<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01226823</url>
  </required_header>
  <id_info>
    <org_study_id>CERTO</org_study_id>
    <nct_id>NCT01226823</nct_id>
  </id_info>
  <brief_title>Ursodeoxycholic Acid And Cholestasis Of Pregnancy</brief_title>
  <acronym>CERTO</acronym>
  <official_title>Intrahepatic Cholestasis Of Pregnancy: Clinical Impact Of Ursodeoxycholic Acid Treatment</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Bologna</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Bologna</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The study is a multicenter randomized double blind placebo controlled trial. The study will
      be conducted on pregnant women with a diagnosis of intrahepatic cholestasis of pregnancy
      (ICP) in third level hospitals (that are also Academic Hospitals).

      Pregnant women at the time of ICP diagnosis will be randomized in two groups:

      Group 1 - will receive placebo and obstetrical monitoring until delivery Group 2 - will
      receive UDCA at the dose of 20 mg/Kg/day and obstetrical monitoring until delivery.

      The hypotheses are that UDCA treatment will be superior to placebo and effective in:

      reducing the rate of prematurity; improving maternal biochemical parameters and symptoms.
    </textblock>
  </brief_summary>
  <overall_status>Withdrawn</overall_status>
  <why_stopped>
    Modified insurance requests by a new law released after its approval.
  </why_stopped>
  <start_date>November 2010</start_date>
  <completion_date type="Anticipated">November 2013</completion_date>
  <primary_completion_date type="Anticipated">November 2013</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of participants with preterm delivery (before week 37)</measure>
    <time_frame>at the time of delivery</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Pruritus on the Visual Analogue Scale</measure>
    <time_frame>from enrollment until delivery</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Transaminases</measure>
    <time_frame>from enrolment until delivery</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Bile Acids</measure>
    <time_frame>from enrolment until delivery</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Fetal movement count</measure>
    <time_frame>from enrolment until delivery</time_frame>
    <description>mother evaluation</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of pregnancies with cardiotocography suggestive of fetal stress</measure>
    <time_frame>from enrolment until delivery</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>APGAR index</measure>
    <time_frame>1 and 5 minutes after birth</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of pregnancies with Green stained amniotic fluid</measure>
    <time_frame>at delivery</time_frame>
    <description>obstetrician evaluation</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">0</enrollment>
  <condition>Intrahepatic Cholestasis of Pregnancy</condition>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>obstetrical monitoring plus placebo</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Ursodeoxycholic acid</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>obstetrical monitoring plus active drug</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ursodeoxycholic Acid</intervention_name>
    <description>300 mg capsules 20 mg/kg body weight/day divided in three administrations per day from enrolment until delivery</description>
    <arm_group_label>Ursodeoxycholic acid</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>300 mg capsules 20 mg/kg body weight/day divided in three administrations per day from enrolment until delivery</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Pregnant state (after week 20 of gestation)

          -  Total Serum BA elevation (&gt;10 micromol/l)

          -  Transaminases elevation (ALT&gt;40 UI/L and AST&gt;37 UI/L)

          -  Occurrence of pruritus

          -  Informed consent signed

        Exclusion Criteria:

          -  Infectious diseases (HBV, HDV, HCV related liver disease, EBV, CMV, HIV infection)

          -  Dermatologic diseases

          -  Metabolic diseases (including alcohol abuse)

          -  Other causes of cholestasis (i.e. PBC; PSC)

          -  Autoimmune liver disease

          -  Obstructive biliary diseases

          -  Drug related pathologies

          -  Known or suspected hyper-sensibility to the drug or the pharmacological class under
             study

          -  Serious clinical conditions that, according to the judgment of the investigator,
             contraindicate the participation to the study (heart, kidney and liver disease)

          -  Use of cholestyramine

          -  Patients not able or not willing to follow the procedures of the protocol

          -  Patients not signing the informed consent

          -  Onset of ICP during of after the 36th week of pregnancy
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Giuseppe Mazzella, Professor</last_name>
    <role>Study Director</role>
    <affiliation>University of Bologna</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Francesco Azzaroli, Professor</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Bologna</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Divisione di Gastroenterologia, IRCCS Casa Sollievo della Sofferenza</name>
      <address>
        <city>San Giovanni Rotondo</city>
        <state>Foggia</state>
        <zip>71013</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UOC Ostetricia e Ginecologia, Ospedale Maggiore</name>
      <address>
        <city>Bologna</city>
        <zip>40100</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>S.Orsola-Malpighi Hospital</name>
      <address>
        <city>Bologna</city>
        <zip>40138</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Gastroenterology and Liver Clinic, Azienda Ospedaliero-Universitaria, University of Modena and Reggio Emilia</name>
      <address>
        <city>Modena</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dept. of Surgical and Gastroenterological Sciences, University of Padova</name>
      <address>
        <city>Padua</city>
        <zip>34100</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Gastroenterology Unit, Policlinic of Palermo</name>
      <address>
        <city>Palermo</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Internal Medicine Department, Gemelli Hospital, Catholic University of Sacred Heart</name>
      <address>
        <city>Rome</city>
        <zip>00168</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Italy</country>
  </location_countries>
  <verification_date>May 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 19, 2010</study_first_submitted>
  <study_first_submitted_qc>October 21, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 22, 2010</study_first_posted>
  <last_update_submitted>May 10, 2016</last_update_submitted>
  <last_update_submitted_qc>May 10, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 12, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Bologna</investigator_affiliation>
    <investigator_full_name>Francesco Azzaroli</investigator_full_name>
    <investigator_title>Assistant Professor</investigator_title>
  </responsible_party>
  <keyword>cholestasis</keyword>
  <keyword>pregnancy</keyword>
  <keyword>ursodeoxycholic acid</keyword>
  <keyword>ICP</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cholestasis</mesh_term>
    <mesh_term>Cholestasis, Intrahepatic</mesh_term>
    <mesh_term>Pregnancy Complications</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ursodeoxycholic Acid</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

